Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Beijing Wandong Medical Technology Co.,Ltd.
  6. News
  7. Summary
    600055   CNE000000PZ1

BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD.

(600055)
  Report
End-of-day quote Shanghai Stock Exchange  -  2023-01-31
21.84 CNY   +1.91%
2022Beijing Wandong Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
2022Beijing Wandong Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
2022Beijing Wandong Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

China Resources Wandong Medical Equipment Co., Ltd announced that it expects to receive CNY 159.60 million in funding from Beijing Pharmaceutical Group Co., Ltd.

12/27/2012 | 11:00pm EST

China Resources Wandong Medical Equipment Co., Ltd (SHSE:600055) announced a private placement of not more than 21,000,000 shares at CNY 7.60 per share for gross proceeds of CNY 159,600,000 to existing investor, Beijing Pharmaceutical Group Co., Ltd. on December 28, 2012. The shares to be subscribed by the investor will have a lock-up period of 36 months from the end of the issuance. The transaction was approved at the 4th session of the 6th directorate meeting.

The issuance requires the approval of the State-owned Assets Supervision and Administration Commission, company's stockholders, and China Securities Regulatory Commission.


ę S&P Capital IQ 2012
Stocks mentioned in the article
ChangeLast1st jan.
ATOS SE 5.21% 12.815 Real-time Quote.35.15%
BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD. 1.91% 21.84 End-of-day quote.11.77%
All news about BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD.
2022Beijing Wandong Medical Technology Co., Ltd. Reports Earnings Results for the Nine Mont..
CI
2022Beijing Wandong Medical Technology Co., Ltd. Reports Earnings Results for the Half Year..
CI
2022Beijing Wandong Medical Technology Co., Ltd. Reports Earnings Results for the First Qua..
CI
2022Beijing Wandong Medical Technology Co., Ltd. announced that it has received CNY 2.06213..
CI
2021Beijing Wandong Medical Technology Co., Ltd. Reports Earnings Results for the Nine Mont..
CI
2021Beijing Wandong Medical Technology Co., Ltd. Reports Earnings Results for the Half Year..
CI
2021Beijing Wandong Medical Technology Co., Ltd. announced that it expects to receive CNY 2..
CI
2021Midea Group Co., Ltd. completed the acquisition of 5% stake in Beijing Wandong Medical ..
CI
2021Midea Group Co., Ltd. completed the acquisition of 24.09% stake in Beijing Wandong Medi..
CI
2021Beijing Wandong Medical Technology Co., Ltd. Reports Earnings Results for the First Qua..
CI
More news
Analyst Recommendations on BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD.
More recommendations
Financials
Sales 2021 1 156 M 171 M 171 M
Net income 2021 183 M 27,2 M 27,2 M
Net cash 2021 1 113 M 165 M 165 M
P/E ratio 2021 69,6x
Yield 2021 0,42%
Capitalization 15 355 M 2 278 M 2 278 M
EV / Sales 2020 3,77x
EV / Sales 2021 10,1x
Nbr of Employees 861
Free-Float 47,1%
Chart BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD.
Duration : Period :
Beijing Wandong Medical Technology Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 21,84
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Xiao Quan Jing Chief Financial Officer
Da Jiang Chairman-Supervisory Board
Zi Qiang Hu Chairman
Ming Xia Zhong Independent Director
Kun Cheng Li Independent Director
Sector and Competitors